D.A. Davidson & CO. Has $119,000 Holdings in Kite Pharma, Inc. (KITE)

D.A. Davidson & CO. held its stake in Kite Pharma, Inc. (NASDAQ:KITE) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,150 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. D.A. Davidson & CO.’s holdings in Kite Pharma were worth $119,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Kite Pharma by 10.3% in the 2nd quarter. BlackRock Inc. now owns 3,995,272 shares of the biopharmaceutical company’s stock valued at $414,190,000 after purchasing an additional 373,301 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Kite Pharma by 16.1% in the 1st quarter. Vanguard Group Inc. now owns 3,661,547 shares of the biopharmaceutical company’s stock valued at $287,395,000 after purchasing an additional 507,289 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Kite Pharma by 235.0% in the 1st quarter. Point72 Asset Management L.P. now owns 819,900 shares of the biopharmaceutical company’s stock valued at $64,354,000 after purchasing an additional 575,178 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Kite Pharma by 19.8% in the 1st quarter. Geode Capital Management LLC now owns 413,148 shares of the biopharmaceutical company’s stock valued at $32,427,000 after purchasing an additional 68,145 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Kite Pharma by 24.2% in the 1st quarter. Bank of New York Mellon Corp now owns 254,995 shares of the biopharmaceutical company’s stock valued at $20,014,000 after purchasing an additional 49,752 shares in the last quarter. 87.72% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/10/11/d-a-davidson-co-has-119000-holdings-in-kite-pharma-inc-kite.html.

A number of brokerages have recently issued reports on KITE. Canaccord Genuity cut shares of Kite Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, August 29th. Wedbush raised shares of Kite Pharma from an “underperform” rating to a “neutral” rating in a research note on Tuesday, August 29th. SunTrust Banks, Inc. cut shares of Kite Pharma from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. Guggenheim cut shares of Kite Pharma from a “buy” rating to a “neutral” rating and set a $128.00 price objective for the company. in a research note on Monday, August 28th. Finally, BTIG Research cut shares of Kite Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, August 28th. Thirteen analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Kite Pharma has a consensus rating of “Hold” and an average target price of $94.68.

In other news, EVP Helen Susan Kim sold 26,649 shares of the business’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $109.28, for a total transaction of $2,912,202.72. Following the completion of the sale, the executive vice president now directly owns 28,763 shares of the company’s stock, valued at $3,143,220.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy L. Moore sold 6,000 shares of the business’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $110.06, for a total transaction of $660,360.00. Following the sale, the executive vice president now directly owns 55,400 shares of the company’s stock, valued at $6,097,324. The disclosure for this sale can be found here. Insiders have sold 194,785 shares of company stock valued at $25,776,870 over the last three months. Insiders own 14.00% of the company’s stock.

Kite Pharma, Inc. (NASDAQ KITE) opened at 179.79 on Wednesday. Kite Pharma, Inc. has a one year low of $39.82 and a one year high of $179.95. The company’s market capitalization is $10.28 billion. The firm has a 50-day moving average of $174.39 and a 200 day moving average of $112.82.

Kite Pharma (NASDAQ:KITE) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.97) by $0.03. The firm had revenue of $10.10 million during the quarter, compared to analyst estimates of $9.59 million. Kite Pharma had a negative net margin of 1,117.44% and a negative return on equity of 59.56%. The business’s revenue was up 110.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.91) earnings per share. Equities research analysts predict that Kite Pharma, Inc. will post ($8.24) earnings per share for the current fiscal year.

Kite Pharma Company Profile

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply